
Opinion|Videos|May 12, 2026
Next-Generation Sequencing and HER2-Mutations in Metastatic NSCLC
Author(s)Joshua K. Sabari, MD
Zongertinib shows strong tolerability in frontline lung cancer cohort, with mostly mild diarrhea, minimal rash, low ILD, and few dose stops.
Advertisement
Episodes in this series

Joshua K. Sabari, MD, explains that it is critical for all patients with metastatic non–small cell lung cancer, regardless of clinical characteristics, to obtain broad panel next-generation sequencing (NGS). He then shares his expert insight on HER2 alterations that may be identified by NGS.
Advertisement
Related to this article

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
2
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5

